Injectable cross-linked collagen implant material

• US 4,582,640 A
• Filed: 10/22/1984
• Issued: 04/15/1986
• Est. Priority Date: 03/08/1982
• Status: Expired due to Term

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Collagen Corp. (Abbvie Incorporated)
• Inventors: Wallace, Donald G., Smestad, Thomas L., McPherson, John
• Primary Examiner(s): Kight, John
• Assistant Examiner(s): Nutter, Nathan M.
• Application Number:
  US06/663,478
• Time in Patent Office: 540 Days
• Field of Search: 260/123.7, 424/177, 424/359, 128/DIG. 8, 514/2, 514/773, 514/801
• US Class Current: 530/356
• CPC Class Codes: A61L 27/24 Collagen
• CPC Class Codes: C07K 14/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• CPC Class Codes: Y10S 128/08 Collagen

Abstract

Cross-linked atelopeptide collagen that is substantially free of residual cross-linking agent is prepared by: reconstituting atelopeptide collagen from solution by neutralizing the solution at a reduced temperature and a hypotonic ionic strength; cross-linking the reconstituted fibers in an aqueous medium at a concentration of 0.1 to 10 mg/ml with glutaraldehyde under conditions that produce cross-linked collagen that when in suspension in physiological saline at a concentration of 35 mg/ml exhibits a shear viscosity whose log varies linearly with the log of the shear rate and is approximated by the formula

log η≦-0.96 log γ+2.3

where γ is the shear rate in sec^-1, log γ is in the range of -6 to +2 and η is the viscosity of the suspension in Pascal-sec; optionally quenching the cross-linking reaction with an amino acid; and separating the cross-linked atelopeptide collagen from the reaction mixture. This collagen is dispersed in an isotonic aqueous medium for use in soft tissue dermal augmentation and is injectable and forms implants that have excellent persistence.

Claims

1. A novel cross-linked atelopeptide collagen for use as an injectable aqueous suspension for augmenting soft tissue that:

(a) is substantially free of residual cross-linking agent;

(b) has greater than about 15 free lysine residues per 1000 amino acid residues; and

(c) is composed substantially of fibrous particles which when in suspension in physiological saline at a concentration of 35 mg/ml exhibit a shear viscosity whose log varies linearly with the log of the shear rate and is approximated by the formula

space="preserve" listing-type="equation">log η

≦

-0.96 log γ

+2.3

where γ

is the shear rate in sec^-1, log γ

is in the range of -6 to +2, and η

is the viscosity of the suspension in Pascal-sec.

2. The collagen of claim 1 wherein the collagen is bovine corium collagen.

3. The collagen of claim 1 wherein the amount of residual cross-linking agent in the collagen is less than about 20 ppm.

4. The collagen of claim 1 wherein the cross-linking agent is one that forms covalent bonds between itself and the collagen.

5. The collagen of claim 4 wherein the cross-linking agent is an aldehyde.

6. The collagen of claim 4 wherein the cross-linking agent is glutaraldehyde.

7. The collagen of claim 6 wherein the number of free lysine residues per 1000 residues is greater than about 20.

8. The collagen of claim 1 wherein the nominal size of the particles is less than about 750 microns.

9. The collagen of claim 8 wherein said size is in the range of about 75 to 750 microns.

10. The collagen of claim 1 wherein the cross-links are substantially intrafibrillar.

26. A collagen implant material for use in augmenting soft tissue in mammals comprising an aqueous suspension of the cross-linked atelopeptide collagen of claim 1.

29. The collagen implant material of claim 26 wherein the concentration of cross-linked atelopeptide collagen in the suspension is about 20 to about 65 mg/ml.

30. A method for augmenting soft tissue in a living mammal comprising injecting the collagen implant material of claim 26 into the mammal at the augmentation site.

31. A method for augmenting soft tissue in a living mammal comprising injecting the collagen implant material of claim 29 into the mammal at the augmentation site.

11. A process for preparing cross-linked atelopeptide collagen for use as an injectable aqueous suspension for augmenting soft tissue comprising:

(a) reconstituting atelopeptide collagen from an acidic aqueous solution by neutralizing the solution at a reduced temperature and at a hypotonic ionic strength;

(b) cross-linking the reconstituted atelopeptide collagen in an aqueous medium at a concentration of about 0.1 to about 10 mg/ml with a cross-linking agent at a concentration of about 0.001% to 0.05% by weight that forms covalent bonds with the collagen under conditions sufficient to produce a fibrous cross-linked collagen that has greater than about 15 free lysine residues per 1000 amino acid residues and that when in suspension in physiological saline at a concentration of 35 mg/ml exhibits a shear viscosity approximated by the formula

space="preserve" listing-type="equation">log η

≦

-0.96 log γ

+2.3

where γ

is the shear rate in sec^-1, log γ

is in the range of -6 to +2, and η

is the viscosity of the suspension in Pascal-sec; and

(c) separating the cross-linked collagen from the cross-linking reaction mixture.

12. The process of claim 11 wherein said concentration of reconstituted atelopeptide collagen in the cross-linking reaction mixture is about 1 to 5 mg/ml.

13. The process of claim 11 wherein the cross-linking agent is an aldehyde.

14. The process of claim 11 wherein the cross-linked atelopeptide collagen contains less than about 20 ppm reactive cross-linking agent.

15. The process of claim 11 wherein the temperature of step (a) is about 10°

C. to about 25°

C., the ionic strength of step (a) is about 0.03 to about 0.1, and the final pH of step (a) is in the range of about 4.9 and about 10.0.

16. The process of claim 15 wherein said final pH is in the range of about 5 and 8.

17. The process of claim 11 wherein the cross-linking agent is glutaraldehyde, and the free lysine content of the cross-linked collagen is greater than about 20 lysine residues per 1000 residues.

18. The process of claim 17 wherein the cross-linking reaction of step (b) is carried out for about one-half hour to about one week.

19. The process of claim 11 wherein the cross-linking reaction is quenched with a quenching agent that reacts with the cross-linking agent.

20. The process of claim 19 wherein the quenching agent is glycine.

21. The process of claim 11 wherein the separation of step (c) includes washing the cross-linked atelopeptide collagen to remove other reaction products and unreacted reactants.

22. The process of claim 11 wherein the cross-links are substantially intrafibrillar.

23. The process of claim 11 wherein:

the collagen is bovine corium collagen;

the temperature of step (a) is about 10°

C. to about 25°

C.;

the ionic strength of step (a) is about 0.03 to about 0.1;

the final pH of step (a) is in the range of about 5 and about 8;

the cross-linking agent is glutaraldehyde;

the concentration of collagen in the cross-linking reaction mixture is about 1 to 5 mg/ml;

the cross-linking reaction is carried out for about one-half hour to about one week;

the separation includes washing the cross-linked atelopeptide collagen to remove other reaction products and unreacted reactants; and

the cross-linked atelopeptide collagen contains less than about 20 ppm reactive aldehyde and has greater than about 20 free lysine residues per 1000 residues.

24. Cross-linked atelopeptide collagen prepared by the process of claim 11.

25. Cross-linked atelopeptide collagen prepared by the process of claim 23.

27. A collagen implant material for use in augmenting soft tissue in mammals comprising an aqueous suspension of the cross-linked atelopeptide collagen of claim 24.

28. A collagen implant material for use in augmenting soft tissue in mammals comprising an aqueous suspension of the cross-linked atelopeptide collagen of claim 25.